A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC #683864, IND #61010) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Temsirolimus (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Jul 2012 Actual end date changed from 1 Feb 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 10 Feb 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 10 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.